<DOC>
	<DOCNO>NCT02963649</DOCNO>
	<brief_summary>To assess safety efficacy paclitaxel drug-eluting balloon IN.PACT 014 versus conventional percutaneous transluminal angioplasty ( PTA ) treatment patient chronic total occlusion infrapopliteal artery .</brief_summary>
	<brief_title>IN.PACT BTK Randomized Study Assess Safety Efficacy IN.PACT 014 vs. PTA</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Age ≥18 year ≤85 year . 2 . Subject informed nature study , agree participate sign EC approve consent form . 3 . Female subject childbearing potential negative pregnancy test ≤7 day procedure willing use reliable method birth control duration study participation ; 4 . Subject document chronic Critical Limb Ischemia ( CLI ) target limb prior study procedure Rutherford Clinical Category 4 5 . 5 . Life expectancy &gt; 1 year Investigator 's opinion . 6 . Reference Vessel Diameter ( RVD ) 2 4 mm , base visual estimation . 7 . Presence document runoff foot 8 . Inflow free flowlimiting lesion confirm angiography . 9 . Successful predilatation ( entire ) target lesion . 1 . Subject unwilling unlikely comply appropriate followup time duration study . 2 . Prior stent ( ) bypass surgery within target vessel ( ) ( include stent place within target vessel index procedure prior randomization . 3 . Previous PTA target vessel within 12 month prior index procedure . 4 . Aneurysm target vessel . 5 . Angiographic evidence thrombus within target limb . 6 . Recent MI stroke &lt; 30 day prior index procedure . 7 . Heart failure Ejection Fraction &lt; 30 % . 8 . Impaired renal function ( GFR &lt; 30 mL/min ) patient dialysis . 9 . Subject vasculitis , systemic Lupus Erythematosus Polymyalgia Rheumatica . 10 . Patient receive systemic corticosteroid therapy . 11 . Inability tolerate concomitant antiplatelet therapy top oral anticoagulation therapy 12 . Known allergy sensitivity heparin , aspirin ( ASA ) , anticoagulant/antiplatelet therapy could substitute , and/or paclitaxel allergy contrast medium adequately pretreated prior index procedure . 13 . The patient currently enrol another investigational device drug trial interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug-eluting angioplasty balloon , Drug coat angioplasty balloon , Experimental , percutaneous transluminal angioplasty ( PTA )</keyword>
</DOC>